> 首页 > 产品 > 一抗 > 其他 > Anti-LILRB2 / ILT4 / CD85d Reference Antibody (Polzastobart)

Anti-LILRB2 / ILT4 / CD85d Reference Antibody (Polzastobart)

Anti-LILRB2 / ILT4 / CD85d Reference Antibody (Polzastobart) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-LILRB2 / ILT4 / CD85d Reference Antibody (Polzastobart) is 97.81%, determined by SEC-HPLC.
Immobilized LILRB2-ECD-His at 2 µg/mL can bind Polzastobart, EC50= 8.336 ng/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q8N423
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	65005 Da

Additional Information
Target/Specificity	LILRB2 / ILT4 / CD85d
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	LILRB2 (HGNC:6606)
Function	Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:11169396, PubMed:12853576, PubMed:16455647, PubMed:20448110, PubMed:27859042). Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:16455647, PubMed:20448110, PubMed:27859042). Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11875462, PubMed:12853576, PubMed:9548455, PubMed:9842885).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Expressed in monocytes and at lower levels in myeloid and plasmacytoid dendritic cells. Expressed in tolerogenic IL10-producing dendritic cells (PubMed:20448110). Expressed in myeloid- derived suppressor cells during pregnancy (PubMed:27859042). Detected at low levels in natural killer (NK) cells. Expressed in B cells